NEW YORK (GenomeWeb) – Second Genome today announced it has entered into a research alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC) in Ireland.

The partners said they will develop therapies to prevent and treat inflammatory bowel disease (IBD) based on the role of the microbiome. To do so, they will analyze data from patients to find new opportunities for treatment. Second Genome has developed a drug discovery platform that integrates microbiome and host biology, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.